|
| US3960150 | 15 Sep 1975 | 1 Jun 1976 | Alza Corporation | Bioerodible ocular device |
| US3961628 | 21 Abr 1975 | 8 Jun 1976 | Alza Corporation | Ocular drug dispensing system |
| US3963025 | 2 Jun 1975 | 15 Jun 1976 | Alza Corporation | Ocular drug delivery device |
| US3976071 | 7 Ene 1974 | 24 Ago 1976 | Dynatech Corporation | Methods of improving control of release rates and products useful in same |
| US3981303 | 31 Jul 1975 | 21 Sep 1976 | Alza Corporation | Bioerodible ocular device |
| US3986510 | 1 Ago 1975 | 19 Oct 1976 | Alza Corporation | Bioerodible ocular device |
| US3993071 | 24 Jul 1975 | 23 Nov 1976 | Alza Corporation | Bioerodible ocular device |
| US3993073 | 3 Mar 1975 | 23 Nov 1976 | Alza Corporation | Novel drug delivery device |
| US4008719 | 2 Feb 1976 | 22 Feb 1977 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4014334 | 2 Feb 1976 | 29 Mar 1977 | Alza Corporation | Laminated osmotic system for dispensing beneficial agent |
| US4135514 | 9 Mar 1977 | 23 Ene 1979 | Alza Corporation | Osmotic releasing system for administering ophthalmic drug to eye of animal |
| US4142526 | 9 Mar 1977 | 6 Mar 1979 | Alza Corporation | Osmotic releasing system with means for changing release therefrom |
| US4290426 | 31 Dic 1979 | 22 Sep 1981 | ALZA Corporation | Dispenser for dispensing beneficial agent |
| US4454148 | 9 Dic 1982 | 12 Jun 1984 | Merck & Co., Inc. | 5-Hydroxy-2-benzothiazolesulfonamide for the topical treatment of elevated intraocular pressure |
| US4659584 | 11 Abr 1986 | 21 Abr 1987 | Dr. Karl Thomae GmbH | Eye rod, process and apparatus for loading the same with solutions or suspensions of active substance |
| US4667032 | 10 Oct 1985 | 19 May 1987 | Merck Frosst Canada, Inc. | Phenothiazone derivatives and analogs |
| US4859667 | 14 Ene 1987 | 22 Ago 1989 | Merck Frosst Canada, Inc. | Pharmaceutical compositions of phenothiazone derivatives and analogs |
| US5104899 | 13 Ago 1990 | 14 Abr 1992 | Sepracor, Inc. | Methods and compositions for treating depression using optically pure fluoxetine |
| US5135592 | 27 Dic 1989 | 4 Ago 1992 | Minnesota Mining and Manufacturing Company | Ultrasonically welded hydrogel ophthalmic lens |
| US5152788 | 27 Dic 1989 | 6 Oct 1992 | Minnesota Mining and Manufacturing Company | Multifocal diffractive ophthalmic lens and method of manufacture |
| US5225196 | 7 Ene 1991 | 6 Jul 1993 | Columbia Laboratories, Inc. | Bioadhesive compositions and methods of treatment therewith |
| US5314419 | 30 Oct 1992 | 24 May 1994 | | Method for dispensing ophthalmic drugs to the eye |
| US5378475 | 21 Feb 1991 | 3 Ene 1995 | University of Kentucky Research Foundation | Sustained release drug delivery devices |
| US5410054 | 20 Jul 1993 | 25 Abr 1995 | Merck Frosst Canada, Inc. | Heteroaryl quinolines as inhibitors of leukotriene biosynthesis |
| US5472436 | 26 Jul 1994 | 5 Dic 1995 | | Ocular appliance for delivering medication |
| US5589511 | 15 Abr 1994 | 31 Dic 1996 | Sepracor Inc. | Method for treating migraine headaches using optically pure S(+) fluoxetine |
| US5618274 | 8 Abr 1994 | 8 Abr 1997 | | Method and device for deep pressurized topical, fornix applied "nerve block" anesthesia |
| US5648396 | 7 Jun 1995 | 15 Jul 1997 | Sepracor Inc. | Methods for treating depression and other disorders using optically pure R (-) fluoxetine and monoamine oxidase inhibitor |
| US5660851 | 5 Jun 1995 | 26 Ago 1997 | Yissum Research Development Company of the Hebrew Univ. of Jerusalem | Ocular inserts |
| US5708035 | 22 May 1995 | 13 Ene 1998 | Sepracor Inc.
McLean Hospital | Methods of use and compositions of R(-) fluoxetine |
| US5766619 | 4 Nov 1994 | 16 Jun 1998 | | Pharmaceutical dosage form for ocular administration and preparation process |
| US5902598 | 28 Ago 1997 | 11 May 1999 | Control Delivery Systems, Inc. | Sustained release drug delivery devices |
| US6110973 | 28 Ene 1999 | 29 Ago 2000 | Sepracor | Methods for treating obesity and weight gain using optically pure (-)-bupropion |
| US6196993 | 19 Abr 1999 | 6 Mar 2001 | Eyelab Group, LLC | Ophthalmic insert and method for sustained release of medication to the eye |
| US6197788 | 27 Sep 1999 | 6 Mar 2001 | Vernalis Research Limited | (-)-mefloquine to block puringergic receptors and to treat movement or neurodegenerative disorders |
| US6200257 | 24 Mar 1999 | 13 Mar 2001 | Proxima Therapeutics, Inc. | Catheter with permeable hydrogel membrane |
| US6277887 | 20 Abr 2000 | 21 Ago 2001 | Sepracor, Inc. | Methods for treating Parkinson's disease using optically pure (-)-bupropion |
| US6337328 | 18 Ago 2000 | 8 Ene 2002 | Sepracor, Inc. | Bupropion metabolites and methods of use |
| US6342496 | 22 Feb 2000 | 29 Ene 2002 | Sepracor Inc. | Bupropion metabolites and methods of use |
| US6369113 | 27 Jun 2001 | 9 Abr 2002 | Sepracor, Inc. | Method for treating depression using optically pure ( |
| US6375972 | 26 Abr 2000 | 23 Abr 2002 | Control Delivery Systems, Inc. | Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof |
| US6451860 | 19 Feb 2002 | 17 Sep 2002 | Sepracor, Inc. | Methods for treating depression and other disorders using optically pure ( |
| US6458374 | 28 Ene 1999 | 1 Oct 2002 | Sepracor, Inc. | Methods and compositions for treating chronic disorders using optically pure ( |
| US6495605 | 13 Mar 2001 | 17 Dic 2002 | Sepracor Inc. | Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure ( |
| US6537194 | 28 Nov 2000 | 25 Mar 2003 | Proxima Therapeutics, Inc. | Catheter with permeable hydrogel membrane |
| US6559188 | 15 Sep 2000 | 6 May 2003 | Novartis AG | Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes |
| US6664397 | 22 Nov 1999 | 16 Dic 2003 | Vernalis Research Limited | Use of ( |
| US6734213 | 17 May 2002 | 11 May 2004 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US6855820 | 17 May 2002 | 15 Feb 2005 | SmithKline Beecham Corporation | Pharmaceutically active morpholinol |
| US6878749 | 16 Ene 2003 | 12 Abr 2005 | Novartis AG | Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
| US6951873 | 3 Mar 2000 | 4 Oct 2005 | Pfizer Inc. | Methods for treating age-related behavioral disorders in companion animals |
| US6998400 | 17 May 2002 | 14 Feb 2006 | Smithkline Beecham Corporation | Pharmaceutically active morpholinol |
| US7034059 | 28 Jun 2002 | 25 Abr 2006 | Sepracor Inc. | Methods of using norfluoxetine |
| US7098206 | 17 May 2002 | 29 Ago 2006 | SmithKline Beecham Corporation | Pharmaceutically active morpholinol |
| US7105333 | 27 Mar 2002 | 12 Sep 2006 | Deadreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 9, the encoded polypeptides and methods based thereon |
| US7112430 | 14 May 2002 | 26 Sep 2006 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| US7125703 | 13 Mar 2002 | 24 Oct 2006 | Dendreon Corporation | Nucleic acid molecules encoding a transmembrane serine protease 7, the encoded polypeptides and methods based thereon |
| US7172892 | 20 Mar 2002 | 6 Feb 2007 | Dendreon Corporation | Nucleic acid molecules encoding serine protease CVSP14, the encoded polypeptides and methods based thereon |
| US7229640 | 18 Dic 2001 | 12 Jun 2007 | SmithKline Beecham p.l.c. | Paroxetine controlled release compositions |
| US7276364 | 20 Nov 2000 | 2 Oct 2007 | Dendreon Corporation | Nucleic acids encoding endotheliases, endotheliases and uses thereof |
| US7585517 | 20 Sep 2004 | 8 Sep 2009 | Macusight, Inc. | Transscleral delivery |
| US7700341 | 2 Feb 2001 | 20 Abr 2010 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| US7767429 | 5 Mar 2004 | 3 Ago 2010 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US7829081 | 4 Mar 2010 | 9 Nov 2010 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7846431 | 4 Mar 2010 | 7 Dic 2010 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7871607 | 23 Feb 2005 | 18 Ene 2011 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7888092 | 30 Oct 2009 | 15 Feb 2011 | Dendreon Corporation | Nucleic acid molecules encoding transmembrane serine proteases, the encoded proteins and methods based thereon |
| US7928132 | 6 Ago 2004 | 19 Abr 2011 | Ohio University | Methods for the amelioration of episodes of acute or chronic ulcerative colitis |
| US8105586 | 15 Jun 2010 | 31 Ene 2012 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US8202517 | 20 Feb 2009 | 19 Jun 2012 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
| US8211428 | 5 Jul 2007 | 3 Jul 2012 | Torrey Pines Institute for Molecular Studies
Catalyst Biosciences, Inc. | Protease screening methods and proteases identified thereby |
| US8222271 | 23 Mar 2007 | 17 Jul 2012 | Santen Pharmaceutical Co., Ltd. | Formulations and methods for vascular permeability-related diseases or conditions |
